カルナバイオサイエンスの株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2011/06/02 | 43,300 | 44,500 | 42,750 | 43,950 | -750 | -1.7% | 635 |
2011/06/01 | 45,350 | 45,350 | 43,700 | 44,700 | -650 | -1.4% | 1,079 |
2011/05/31 | 45,500 | 46,500 | 44,200 | 45,350 | -2,750 | -5.7% | 2,718 |
2011/05/30 | 50,800 | 54,200 | 47,500 | 48,100 | +900 | +1.9% | 10,172 |
2011/05/27 | 44,700 | 48,000 | 41,300 | 47,200 | +3,200 | +7.3% | 4,622 |
2011/05/26 | 44,000 | 49,000 | 42,050 | 44,000 | +2,000 | +4.8% | 6,087 |
2011/05/25 | 46,050 | 46,250 | 40,350 | 42,000 | -4,250 | -9.2% | 1,651 |
2011/05/24 | 47,600 | 51,900 | 44,550 | 46,250 | -2,750 | -5.6% | 4,119 |
2011/05/23 | 49,000 | 49,000 | 49,000 | 49,000 | +7,000 | +16.7% | 1,068 |
2011/05/20 | 34,500 | 42,000 | 34,000 | 42,000 | +7,000 | +20% | 162 |
2011/05/19 | 34,800 | 35,000 | 34,550 | 35,000 | -500 | -1.4% | 50 |
2011/05/18 | 33,500 | 35,500 | 33,500 | 35,500 | +650 | +1.9% | 34 |
2011/05/17 | 34,100 | 35,000 | 33,200 | 34,850 | +150 | +0.4% | 55 |
2011/05/16 | 35,600 | 35,800 | 34,500 | 34,700 | -2,300 | -6.2% | 78 |
2011/05/13 | 38,000 | 38,000 | 36,050 | 37,000 | -850 | -2.2% | 98 |
2011/05/12 | 38,000 | 38,000 | 36,800 | 37,850 | +900 | +2.4% | 74 |
2011/05/11 | 36,600 | 38,100 | 36,500 | 36,950 | +50 | +0.1% | 55 |
2011/05/10 | 37,800 | 37,800 | 35,800 | 36,900 | -800 | -2.1% | 74 |
2011/05/09 | 38,900 | 38,900 | 36,850 | 37,700 | +450 | +1.2% | 55 |
2011/05/06 | 36,500 | 37,800 | 36,150 | 37,250 | +50 | +0.1% | 67 |
2011/05/02 | 36,000 | 37,600 | 36,000 | 37,200 | +1,150 | +3.2% | 195 |
2011/04/28 | 37,000 | 37,200 | 36,000 | 36,050 | +550 | +1.5% | 429 |
2011/04/27 | 36,550 | 39,550 | 34,750 | 35,500 | +2,450 | +7.4% | 1,509 |
2011/04/26 | 32,000 | 34,750 | 31,400 | 33,050 | +3,300 | +11.1% | 516 |
2011/04/25 | 31,000 | 31,400 | 29,720 | 29,750 | -750 | -2.5% | 97 |
2011/04/22 | 28,750 | 30,900 | 28,750 | 30,500 | +1,800 | +6.3% | 98 |
2011/04/21 | 29,190 | 29,190 | 28,420 | 28,700 | +340 | +1.2% | 38 |
2011/04/20 | 28,310 | 29,000 | 28,300 | 28,360 | +10 | ±0% | 58 |
2011/04/19 | 28,750 | 28,750 | 28,010 | 28,350 | -400 | -1.4% | 39 |
2011/04/18 | 28,300 | 28,800 | 28,210 | 28,750 | +560 | +2% | 67 |
2011/04/15 | 28,350 | 28,800 | 28,150 | 28,190 | -140 | -0.5% | 85 |
2011/04/14 | 28,050 | 28,400 | 27,970 | 28,330 | +330 | +1.2% | 106 |
2011/04/13 | 29,050 | 29,100 | 27,910 | 28,000 | -1,500 | -5.1% | 348 |
2011/04/12 | 29,600 | 29,950 | 29,000 | 29,500 | -500 | -1.7% | 109 |
2011/04/11 | 29,300 | 30,000 | 29,300 | 30,000 | +10 | ±0% | 79 |
2011/04/08 | 30,000 | 30,300 | 29,150 | 29,990 | -10 | ±0% | 73 |
2011/04/07 | 30,400 | 30,550 | 29,900 | 30,000 | -500 | -1.6% | 110 |
2011/04/06 | 30,700 | 30,900 | 30,500 | 30,500 | ±0 | ±0% | 87 |
2011/04/05 | 31,000 | 31,250 | 30,500 | 30,500 | -750 | -2.4% | 59 |
2011/04/04 | 31,900 | 31,900 | 30,500 | 31,250 | -250 | -0.8% | 75 |
2011/04/01 | 31,000 | 31,950 | 30,800 | 31,500 | +350 | +1.1% | 67 |
2011/03/31 | 31,200 | 31,800 | 31,000 | 31,150 | -850 | -2.7% | 69 |
2011/03/30 | 30,700 | 32,400 | 30,200 | 32,000 | +1,000 | +3.2% | 87 |
2011/03/29 | 31,000 | 31,000 | 29,900 | 31,000 | -450 | -1.4% | 120 |
2011/03/28 | 32,000 | 32,000 | 30,200 | 31,450 | -550 | -1.7% | 91 |
2011/03/25 | 32,300 | 32,450 | 30,050 | 32,000 | -300 | -0.9% | 167 |
2011/03/24 | 32,150 | 32,300 | 31,650 | 32,300 | +250 | +0.8% | 76 |
2011/03/23 | 33,000 | 33,900 | 32,050 | 32,050 | -1,850 | -5.5% | 138 |
2011/03/22 | 31,800 | 33,900 | 29,900 | 33,900 | +5,000 | +17.3% | 650 |
2011/03/18 | 25,900 | 29,200 | 25,900 | 28,900 | +3,800 | +15.1% | 277 |
3301~
3350
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「カルナバイオ」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
カルナバイオ | 31,000円 | -43.1% | - | 0.00% | - | 1.84倍 |
|
キナーゼタンパク質の販売や受託試験など創薬初期の支援事業が柱。キナーゼ阻害剤で創薬も |
ノイルイミューン | 17,300円 | -97.8% | - | 0.00% | - | 1.50倍 |
|
独自技術用いたCAR-T細胞免疫療法で抗がん剤を複数開発中。中外製薬とライセンス契約 |
日ケミファ | 151,100円 | +2.5% | - | 3.31% | 90.86倍 | 0.29倍 |
|
中堅後発薬メーカー。長期収載品の主力は痛風薬ウラリット。新薬開発、検査薬事業を中期強化 |
VIS | 89,000円 | +87.8% | +265.7% | 0.00% | 53.45倍 | 2.45倍 |
|
mRNA標的低分子創薬技術を製薬会社に提供。共同創薬研究などによる契約金収入が柱 |
クリングル | 84,500円 | +240.0% | - | 0.00% | - | 2.75倍 |
|
細胞の増殖、保護、修復などの機能があるHGFタンパク質を用いて、難治性疾患治療薬を開発 |
市場注目の銘柄
チャート関連のコラム